HomeAI · summaries
Storia in 4 fonti
BeOne’s Brukinsa succeeds in frontline mantle cell lymphoma study
BeOne's Brukinsa plus rituximab cut disease progression risk by 43% versus chemoimmunotherapy in a Phase 3 frontline mantle cell lymphoma trial.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
fiercepharma.com
BeOne’s Brukinsa hits goal in mantle cell lymphoma confirmatory trial
A Brukinsa regimen has delivered a large progression-free survival (PFS) benefit in what BeOne Medicines called a “new chemotherapy-free standard” in first-line mantle cell…
- ·
endpoints.news
BeOne’s Brukinsa succeeds in frontline mantle cell lymphoma study
BeOne's Brukinsa plus rituximab cut disease progression risk by 43% versus chemoimmunotherapy in a Phase 3 frontline mantle cell lymphoma trial.
